Tirzepatide: Uses, Benefits, Dosage and Safety

Tirzepatide is a once-weekly injection licensed for type 2 diabetes as Mounjaro and for weight management as Zepbound. It is the same molecule under two names, and it is currently the most effective weight loss medicine a doctor can prescribe.

What makes it unusual is that it acts on two gut hormone receptors rather than one. In the trials that produced its licence, adults without diabetes lost about 20% of their body weight over 72 weeks, and when it was compared directly against semaglutide it won on both weight and blood sugar.

The part that gets less attention is what it does not yet have. Semaglutide has a completed trial showing fewer heart attacks and strokes. Tirzepatide's equivalent is still running. On weight the newer drug is ahead; on proven hard outcomes it is not.

What is tirzepatide?#

Tirzepatide is a synthetic peptide of 39 amino acids, built to activate two receptors the body already uses to manage appetite and blood sugar after a meal. It is given as a subcutaneous injection once a week from a pre-filled pen.

The vocabulary here is shared with the rest of this class, and what peptides actually are covers it if any of it is unfamiliar.

Where it comes from#

It is a laboratory molecule based on the structure of GIP, modified so that it also binds the GLP-1 receptor, and carrying a fatty acid chain that lets it stick to albumin in the blood. That last detail is what stretches its life from minutes to about five days, which is what makes weekly dosing possible.

It was approved in the United States for type 2 diabetes in 2022, for weight management in 2023, and for obstructive sleep apnoea in people with obesity in 2024.

Proposed mechanisms of action#

Two receptors, and an argument about the second one.

• GLP-1. The appetite receptor. Activating it slows stomach emptying and reduces hunger signalling in the brain, so meals finish sooner and the gap before the next one feels longer.
• GIP. The other main incretin, released from the gut after eating. Its role was thought unhelpful for weight for years, and the tirzepatide results forced a rethink rather than settling the question.

Whether the extra weight loss comes specifically from the GIP arm or from the combination of the two has not been isolated in people. Both mechanisms are present, the result is larger than GLP-1 alone produces, and the attribution is inference rather than measurement.

What tirzepatide is claimed to do#

Large, sustained weight loss#

The claim is that a person loses roughly a fifth of their body weight and keeps it off while they keep taking it.

Dual agonism at the GLP-1 and GIP receptors reduces appetite and alters how the body handles fat and sugar after eating.

In practice that describes meals ending earlier without effort, and the running background negotiation about food going quiet. People consistently describe the change as the absence of a fight rather than the presence of willpower.

This was measured in SURMOUNT-1, a randomised placebo-controlled trial in adults with obesity and without diabetes, where the highest dose produced about 20% mean body weight reduction over 72 weeks.

Better blood sugar control#

The claim is that a person with type 2 diabetes sees their HbA1c fall further than on the drug that was previously standard.

Both receptors increase insulin release in response to a meal and reduce the liver's tendency to push stored sugar into the blood between them.

Put another way, the pancreas responds faster when food arrives and the liver holds back when it has not. Average blood sugar falls as a consequence of both.

This was measured in SURPASS-2, which compared tirzepatide directly against semaglutide in people with type 2 diabetes and found greater reductions in both HbA1c and weight. A head-to-head trial is a much stronger form of evidence than two separate trials compared afterwards, and it is worth noting how rarely this class provides one.

Fewer breathing interruptions in sleep#

The claim is that obstructive sleep apnoea becomes measurably less severe, and this one has its own licence rather than being a secondary finding.

The mechanism is mechanical. Fat around the neck and pharynx narrows the airway and makes it more likely to collapse during sleep, and reducing that tissue widens the margin.

For a person the difference is between waking unrefreshed every morning for years and sleeping through, which is a larger day-to-day change than the number on the scale.

This was measured in the SURMOUNT-OSA trials, where apnoea events per hour fell substantially and enough participants improved that the condition's management changed for a proportion of them. This is a measured clinical outcome rather than a weight proxy.

Improvement in how fat and sugar are handled#

The claim is that the metabolic picture improves beyond what the weight loss alone would predict.

The GIP arm appears to affect how fat is stored and cleared after a meal, independently of how much is eaten.

Whether that matters to you depends on whether the goal is the scale or the blood work, and the two do not always move together.

This is the least settled of the four claims. The evidence is suggestive, the mechanism is plausible, and nobody has separated the GIP contribution from the GLP-1 contribution in a human trial.

What the evidence actually supports#

• Species and route. Human, at the route people actually use, in large randomised placebo-controlled trials. No inference from rodents is required.
• Concentration of sources. Almost all of the pivotal work is sponsored by Eli Lilly. That is normal at this stage and it remains the most important single fact about the evidence base. Independent replication is thinner than the volume of trials suggests.
• Human data. The SURMOUNT and SURPASS programmes are published in full, across tens of thousands of participants, including one direct head-to-head against the previous standard. This is the strongest tier of evidence anything on this site carries.
• What has not been looked at. Cardiovascular outcomes. The trial is running and has not reported, so the claim that tirzepatide reduces heart attacks is currently an extrapolation from weight and blood sugar rather than a finding.

The summary a reader can take away: on weight and blood sugar this is as well evidenced as medicine gets. On whether it makes people live longer, nobody knows yet, and semaglutide does have that answer.

Side effects and safety profile#

The common problems are digestive: nausea, diarrhoea, constipation, vomiting and reflux, worst in the first weeks and in the days after each dose increase. Most settle. The escalation schedule exists to blunt them, and moving through it faster than prescribed is the most common self-inflicted misery on this class of drug.

Two things belong in a different category from tolerability.

The label also rules the drug out for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. That contraindication comes from tumours seen in rodents which have not been demonstrated in humans, and it is on the label regardless, which means it is a question a prescriber will ask.

The muscle question applies here more than to the weaker drugs in the class, precisely because the total loss is larger. Rapid weight loss takes lean tissue along with fat. Protein intake and resistance training are the levers that exist, and both work better started early than retrofitted.

How it is dosed and administered#

Tirzepatide has an approved human indication and a real label, which makes this section short.

It is a once-weekly subcutaneous injection from a pre-filled pen, into the stomach, thigh or upper arm, starting at a low dose and stepping up at roughly four-week intervals. The schedule is a tolerance ramp rather than a delay.

Dose, escalation and stopping are decisions for the prescriber who knows the person's history. That genuinely is the whole of what needs saying: unlike most compounds covered on this site, there is a label, it was written from the trial data, and it is more reliable than anything reported second-hand.

Where a vial has been obtained outside that route, nothing on its label establishes identity or concentration. Third-party testing and what a COA proves covers what a certificate does and does not settle.

Tirzepatide compared with semaglutide and retatrutide#

Against semaglutide#

This is the one comparison in the class that was actually measured. SURPASS-2 put the two against each other and tirzepatide produced greater reductions in both HbA1c and weight.

The counterweight is SELECT, semaglutide's cardiovascular outcomes trial, which found roughly 20% fewer heart attacks, strokes and cardiovascular deaths in people who already had heart disease. Tirzepatide has no equivalent completed trial. For someone whose main risk is cardiac rather than metabolic, the older drug still has the better evidence.

Against retatrutide#

Retatrutide adds a third receptor, glucagon, and reported up to 28.3% mean weight loss in phase 3. It is not approved anywhere and a US filing is planned for 2027. The head-to-head against tirzepatide is running rather than finished, so the gap between 20% and 28% is a comparison across separate trials, which is the least reliable kind.

Against surgery#

The average results now overlap with some bariatric procedures on weight alone. Surgery has decades of durability and mortality data behind it that no drug in this class has yet, and the two have not been compared head to head over the long term.

Frequently asked questions#

Is tirzepatide better than semaglutide?

On weight and blood sugar, a direct trial says yes. On cardiovascular outcomes, semaglutide has the completed evidence and tirzepatide does not, so the honest answer depends on which question is being asked.

Do I have to stay on it?

Trials that withdrew it saw substantial weight regain. It behaves like a treatment for an ongoing condition rather than a course with an end date, which is a fact about how the drug works rather than a failure of resolve.

Why are there two brand names?

Mounjaro is licensed for type 2 diabetes and Zepbound for weight management. Same molecule, two licences. The separation is regulatory rather than pharmacological.

How long until it works?

Appetite usually shifts within the first week or two, well before the scale moves. The weight curve in SURMOUNT-1 kept falling for more than a year before flattening.

Does it cause thyroid cancer?

No human case has been demonstrated. The signal comes from rodents, it sits on the label, and it rules out use for people with the specific inherited conditions named there.

Key takeaways#

• Tirzepatide is a dual GLP-1 and GIP receptor agonist, approved for type 2 diabetes, weight management and obstructive sleep apnoea.
• SURMOUNT-1 reported about 20% mean body weight reduction over 72 weeks, and SURPASS-2 beat semaglutide directly on both weight and blood sugar.
• The sleep apnoea licence rests on a measured clinical outcome rather than on weight as a proxy.
• Severe abdominal pain that does not settle is a same-day medical question, and the label excludes anyone with a personal or family history of medullary thyroid carcinoma or MEN2.
• It has no completed cardiovascular outcomes trial. Semaglutide does, which is why the older drug remains first choice for some prescribers.

References#

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022. The SURMOUNT-1 trial.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021. The SURPASS-2 head-to-head.
3. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, 2024. The SURMOUNT-OSA trials.
4. The compound page on this site: tirzepatide.